Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer

Table 4 Agents targeting the EGFR family under investigation or approved for metastatic breast cancer

Agent	Class of agent	Target	Stage of development in breast cancer
Trastuzumab	Monoclonal antibody	HER2	Approved
Lapatinib	TKI	EGFR, HER2	Approved
Erlotinib	TKI	EGFR	II
Cetuximab	Monoclonal antibody	EGFR	II
Gefitinib	TKI	EGFR	Discontinued

EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; TKI, tyrosine kinase inhibitor.

ISSN: 1465-542X